JPMorgan Chase & Co. Has $6.90 Million Stock Position in Sera Prognostics, Inc. (NASDAQ:SERA)

JPMorgan Chase & Co. grew its stake in Sera Prognostics, Inc. (NASDAQ:SERA) by 7,357.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 884,867 shares of the company’s stock after acquiring an additional 873,002 shares during the quarter. JPMorgan Chase & Co.’s holdings in Sera Prognostics were worth $6,902,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SERA. Barclays PLC boosted its stake in Sera Prognostics by 321.6% in the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after buying an additional 30,093 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after purchasing an additional 75,441 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after purchasing an additional 47,969 shares during the last quarter. Quest Partners LLC increased its position in shares of Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares in the last quarter. Finally, State Street Corp lifted its holdings in Sera Prognostics by 8.8% during the 3rd quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after purchasing an additional 34,479 shares during the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, General Counsel Benjamin Jackson sold 13,272 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $7.42, for a total value of $98,478.24. Following the completion of the sale, the general counsel now owns 128,473 shares of the company’s stock, valued at $953,269.66. This trade represents a 9.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Paul Kearney sold 4,078 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $29,850.96. Following the completion of the transaction, the insider now owns 176,889 shares of the company’s stock, valued at $1,294,827.48. This trade represents a 2.25 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 93,215 shares of company stock valued at $666,835. 15.80% of the stock is currently owned by corporate insiders.

Sera Prognostics Stock Up 3.8 %

NASDAQ:SERA opened at $6.61 on Thursday. The firm has a market cap of $223.23 million, a PE ratio of -6.68 and a beta of 0.86. The company’s 50-day moving average price is $7.44 and its two-hundred day moving average price is $7.31. Sera Prognostics, Inc. has a 12 month low of $4.98 and a 12 month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the prior year, the firm earned ($0.23) earnings per share. On average, research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.